Todd L Lowary1. 1. Alberta Glycomics Centre and Department of Chemistry, University of Alberta , Gunning-Lemieux Chemistry Centre, Edmonton, Alberta T6G 2G2, Canada.
Abstract
The cell surface (or cell wall) of bacteria is coated with carbohydrate (or glycan) structures that play a number of important roles. These include providing structural integrity, serving as a permeability barrier to extracellular compounds (e.g., drugs) and modulating the immune system of the host. Of interest to this Account is the cell wall structure of mycobacteria. There are a host of different mycobacterial species, some of which cause human disease. The most well-known is Mycobacterium tuberculosis, the causative agent of tuberculosis. The mycobacterial cell wall is characterized by the presence of unusual carbohydrate structures that fulfill the roles described above. However, in many cases, a molecular-level understanding of how mycobacterial cell wall glycans mediate these processes is lacking. Inspired by a seminar he heard as a postdoctoral fellow, the author began his independent research program with a focus on the chemical synthesis of mycobacterial glycans. The goals were not only to develop synthetic approaches to these unique structures but also to provide molecules that could be used to probe their biological function. Initial work addressed the preparation of fragments of two key polysaccharides, arabinogalactan and lipoarabinomannan, which contain large numbers of sugar residues in the furanose (five-membered) ring form. At the time these investigations began, there were few methods reported for the synthesis of oligosaccharides containing furanose rings. Thus, early in the program, a major area of interest was methodology development, particularly for the preparation of 1,2-cis-furanosides. To solve this challenge, a range of conformationally restricted donors have been developed, both in the author's group and others, which provide 1,2-cis-furanosidic linkages with high stereoselectivity. These investigations were followed by application of the developed methods to the synthesis of a range of target molecules containing arabinofuranose and galactofuranose residues. These molecules have now found application in biochemical, immunological, and structural biology investigations, which have shed light on their biosynthesis and how these motifs are recognized by both the innate and adaptive immune systems. More recently, attention has been directed toward the synthesis of another class of immunologically active mycobacterial cell wall glycans, the extractable glycolipids. In this case, efforts have been primarily on phenolic glycolipids, and the compounds synthesized have been used to evaluate their ability to modulate cytokine release. Over the past 20 years, the use of chemical synthesis to provide increasingly complex glycan structures has provided significant benefit to the burgeoning field of mycobacterial glycobiology. Through the efforts of groups from around the globe, access to these compounds is now possible via relatively straightforward methods. As the pool of mycobacterial glycans continues to grow, so too will our understanding of their role in disease, which will undoubtedly lead to new strategies to prevent or treat mycobacterial infections.
The cell surface (or cell wall) of bacteria is coated with carbohydrate (or glycan) structures that play a number of important roles. These include providing structural integrity, serving as a permeability barrier to extracellular compounds (e.g., drugs) and modulating the immune system of the host. Of interest to this Account is the cell wall structure of mycobacteria. There are a host of different mycobacterial species, some of which cause human disease. The most well-known is Mycobacterium tuberculosis, the causative agent of tuberculosis. The mycobacterial cell wall is characterized by the presence of unusual carbohydrate structures that fulfill the roles described above. However, in many cases, a molecular-level understanding of how mycobacterial cell wall glycans mediate these processes is lacking. Inspired by a seminar he heard as a postdoctoral fellow, the author began his independent research program with a focus on the chemical synthesis of mycobacterial glycans. The goals were not only to develop synthetic approaches to these unique structures but also to provide molecules that could be used to probe their biological function. Initial work addressed the preparation of fragments of two key polysaccharides, arabinogalactan and lipoarabinomannan, which contain large numbers of sugar residues in the furanose (five-membered) ring form. At the time these investigations began, there were few methods reported for the synthesis of oligosaccharides containing furanose rings. Thus, early in the program, a major area of interest was methodology development, particularly for the preparation of 1,2-cis-furanosides. To solve this challenge, a range of conformationally restricted donors have been developed, both in the author's group and others, which provide 1,2-cis-furanosidic linkages with high stereoselectivity. These investigations were followed by application of the developed methods to the synthesis of a range of target molecules containing arabinofuranose and galactofuranose residues. These molecules have now found application in biochemical, immunological, and structural biology investigations, which have shed light on their biosynthesis and how these motifs are recognized by both the innate and adaptive immune systems. More recently, attention has been directed toward the synthesis of another class of immunologically active mycobacterial cell wall glycans, the extractable glycolipids. In this case, efforts have been primarily on phenolic glycolipids, and the compounds synthesized have been used to evaluate their ability to modulate cytokine release. Over the past 20 years, the use of chemical synthesis to provide increasingly complex glycan structures has provided significant benefit to the burgeoning field of mycobacterial glycobiology. Through the efforts of groups from around the globe, access to these compounds is now possible via relatively straightforward methods. As the pool of mycobacterial glycans continues to grow, so too will our understanding of their role in disease, which will undoubtedly lead to new strategies to prevent or treat mycobacterial infections.
A challenge I, and presumably others who
train graduate students,
face is getting them to attend departmental seminars. At the start
of a new academic year, I often hear complaints from my students about
seminars being a distraction from research and that their attending
a talk that is not directly aligned with their interests is a poor
use of time. In response, I point out that this is an excellent opportunity
to learn new things and that seminar attendance is, after all, something
I require. I also describe a situation where my attending a seminar,
the title of which was not directly aligned with what I thought were
my “research interests”, had a profound impact on my
career.The lecture[1] was given at
the 17th International
Carbohydrate Symposium in 1994, the time I was beginning to develop
proposals for my applications for independent faculty positions. The
speaker was Patrick Brennan of Colorado State University, a pioneer
and international leader in determining the structures and biosynthesis
of the highly complex carbohydrates (glycans) found in the cell wall
of mycobacteria, including the organism that causes tuberculosis, Mycobacterium tuberculosis. Brennan is an engaging speaker
and the molecules he presented had structures unlike anything I had
ever seen. I knew immediately that mycobacterial glycans were something
I had to study in my independent career.The mycobacterial cell
wall is a highly complex structure composed
largely of carbohydrates and lipids (Figure ).[2−4] The major components are two lipidated
polysaccharides, the mycolyl–arabinogalactan (AG) complex and
lipoarabinomannan (LAM). The structures (Figure ) of both AG and LAM are characterized by
the presence of a large number of sugar residues in the furanose (five-membered)
ring form. It was these molecules that so intrigued me in Brennan’s
talk. AG is composed nearly exclusively of such monosaccharides, galactofuranose
(Galf) and arabinofuranose (Araf), while LAM contains both Araf and mannopyranose
residues. In 1994, there had been relatively few investigations on
the synthesis of furanose-containing glycans. For a basic science
perspective, this seemed to be an excellent area in which to build
a research program. Moreover, from a practical standpoint I was excited
by the possibility of the target molecules being applied to study
the biology of an organism that causes a disease of great importance
and one for which drug resistance had become (and remains) a problem:
tuberculosis.
Figure 1
Representation of the mycobacterial cell wall with all
major classes
of glycans shown. LAM, lipoarabinomannan; PGLs, phenolic glycolipids;
GPLs, glycopeptidolipids; LOSs, lipooligosaccharides. Reproduced with
permission from ref (5). Copyright 2015 John Wiley & Sons.
Figure 2
Composite structures of mycobacterial arabinogalactan (AG) and
lipoarabinomannan (LAM).
Representation of the mycobacterial cell wall with all
major classes
of glycans shown. LAM, lipoarabinomannan; PGLs, phenolic glycolipids;
GPLs, glycopeptidolipids; LOSs, lipooligosaccharides. Reproduced with
permission from ref (5). Copyright 2015 John Wiley & Sons.Composite structures of mycobacterial arabinogalactan (AG) and
lipoarabinomannan (LAM).
Synthesis of Arabinofuranosides
In charting a course of
action, the initial goal was to develop
chemistry that could be used for the synthesis of Araf-containingoligosaccharides, which could then serve as substrates
for the glycosyltransferases involved in AG and LAM biosynthesis or
as ligands for Araf-binding proteins. An initial
challenge in the synthesis of furanosides is to obtain derivatives
in the less thermodynamically stable five-membered ring form.[6] There are a number of methods for doing this,
each with their pros and cons. For arabinose, we found the most straightforward
access was through a classic method: Fischer glycosylation under kinetic
control. We adopted and refined a reported method[7] to prepare methyl glycoside 1 in two steps
from d-arabinose (Scheme A). This method is robust enough that it can be reliably
done in undergraduate teaching laboratories.[8] We subsequently could convert 1, in one step, into
the corresponding thioglycoside 2(9) and then into other glycosyldonors (e.g., 3–5).[10,11] Early in our investigations,
we also developed an alternate approach to the Araf system though ozonolysis of protected glucal derivatives (6 → 7, Scheme B).[12] This latter
method was useful for the preparation of 13C labeled materials
(from commercially available 13C-labeled d-glucose),
which were of interest for NMR spectroscopic studies. However, it
is less convenient than Fischer glycosylation for the preparation
of materials on large scale.
Scheme 1
Access to the Arabinofuranose Ring
System and Donors (3–5) for the Synthesis
of Arabinofuranose-Containing
Glycans
The Araf residues in AG and LAM are found as part
of α-(1,2-trans) and β-(1,2-cis) linkages (Figure A). We assumed that the α-linkages could be straightforwardly
assembled from glycosyldonors possessing O-2 acylation, for example, 2. The acyl groups, through neighboring group participation,
would ensure the 1,2-trans stereochemistry. Indeed,
the use of donors analogous to 2 were used by graduate
student Joe Ayers to synthesize α-Araf-containingglycans (e.g., 8 and 9, Figure B), which could then be used
as acceptor substrates for mycobacterial arabinosyltransferases.[13]
Figure 3
(A) Structures of the α-Araf and
β-Araf ring systems and (B) structures of α-Araf-containing oligosaccharides 8 and 9.
(A) Structures of the α-Araf and
β-Araf ring systems and (B) structures of α-Araf-containingoligosaccharides 8 and 9.On the other hand, we anticipated
that stereoselective access to
the β-Araf-linkages would be more difficult,
given their stereochemical similarity to β-mannopyranosides.
The stereochemistry of these 1,2-cis-β systems
is such that one can rely on neither neighboring group participation
nor thermodynamics (through the anomeric effect) to give the desired
product.[14] That said, we did explore the
possibility that 2-O-benzylated donors (e.g., 3, 4) could be used to access β-Araf linkages. We discovered that by carefully controlling
the reaction conditions, some donor and acceptor pairs could be coupled
with good to excellent β-selectivity.[10] Using this approach a postdoctoral fellow, Haifeng Yin, could synthesize
a panel of mycobacterial arabinofuranoside fragments, including the
common Ara6 motif (10, Figure ), which is found at the nonreducing terminus
of both AG and LAM.[11] Subsequent work from
the Kim group showed similar results with another class of glycosyldonors.[15]
Figure 4
Structure of the Ara6 motif (as the methyl
glycoside), which is
present in both AG and LAM.
Structure of the Ara6 motif (as the methyl
glycoside), which is
present in both AG and LAM.Although we could access many targets through donors such
as 3, the lack of generality of the method for synthesizing
the
β-Arafglycosides was a limitation. Around
the same time, the Crich group had demonstrated the influence of conformational
restriction of the pyranose ring in the synthesis of β-mannopyranosides.
In particular, it was shown that donors possessing a 4,6-O-benzylidene acetal (e.g., 11, Figure A) could, under the proper conditions, produce
β-mannopyranosides (12) with high stereoselectivity,
whereas donors lacking this cyclic acetal (13) are unselective
or even α-selective.[16,17] It was later demonstrated
that the torsional restraints induced by the benzylidene acetal led
to the in situ generation of an α-mannopyranosyl triflate (15, Figure B), which could then react with the alcohol in an SN2-like
manner to produce the β-mannopyranoside. In the absence of this
cyclic protecting group an ion-pair structure (e.g., 16) is produced in place of 15, which leads to increases
in the amount of α-glycoside product.[18,19]
Figure 5
(A)
Studies by Crich on the synthesis of β-mannopyranosides,
showing the β-selective glycosyl triflate intermediate (15) and an α-selective/unselective intermediate (16).[19] (B) A conformationally restricted
Araf-thioglycoside (17).
(A)
Studies by Crich on the synthesis of β-mannopyranosides,
showing the β-selective glycosyl triflate intermediate (15) and an α-selective/unselective intermediate (16).[19] (B) A conformationally restricted
Araf-thioglycoside (17).These studies prompted us to consider an analogous
approach for
synthesis of β-Araf linkages. The obvious extension
would be to prepare a benzylidene acetal such as 17 (Figure B). However, we were
aware that the yield of compounds of this type was generally low given
the strain present in the trans-fused 5/6 ring system.
These considerations were underway when, for other reasons, we prepared
a series of 2,3-anhydro-furanoside thioglycosides (e.g., 18, Figure ). Out of
simple curiosity, the postdoctoral fellow carrying out this work,
Raj Gadikota, tested how 18 behaved in glycosylation
reactions. We were surprised to discover that it was indeed a highly
stereoselective glycosyldonor, in most cases producing a single glycoside
product. Even more surprising was that the product obtained was the
one in which the glycosidic linkage was cis to the
epoxide moiety, 19.[20] We subsequently
showed that the sulfoxide derivative 20 gave the same
results when glycosylations were done under “Crich”
conditions.[18,19] These results provided an alternative,
albeit indirect, route to β-arabinofuranosides: glycosylation
with donors such as 18a/18b, followed by regioselective
opening of the epoxide ring (19) with a nucleophile resulting
in 20.[21]
Figure 6
(A) 2,3-anhydrosugar
donors 18a/18b and their use
in the synthesis of β-arabinofuranosides (20).
(B) Postulated complex (21) formed in (−)-sparteine-mediated
nucleophilic opening of O-5 deprotonated 2,3-anhydro-β-d-lyxofuranosides (e.g., 19) by lithium alkoxides.
(A) 2,3-anhydrosugardonors 18a/18b and their use
in the synthesis of β-arabinofuranosides (20).
(B) Postulated complex (21) formed in (−)-sparteine-mediated
nucleophilic opening of O-5 deprotonated 2,3-anhydro-β-d-lyxofuranosides (e.g., 19) by lithium alkoxides.The opening of the epoxide in
a regioselective manner proved to
be more challenging than expected. Previous work[22] suggested that these substrates should be predisposed to
nucleophilic attack at the desired C-3 position; however, with alkoxides
as the nucleophile, the selectivities were modest.[21] Moreover, the substrates were quite robust. Heating at
over 100 °C was necessary for reasonable rates to be achieved.
A serendipitous discovery that lithium alkoxides provided better regioselectivity
than their sodium or potassium counterparts led ultimately to a solution.
We investigated the possibility that lithium binding additives might
enhance the rate and regioselectivity of the reaction. After screening
a number of such additives, graduate student Chris Callam found that
both a rate enhancement and a substantial increase in regiocontrol
could be obtained with (−)-sparteine. The temperature could
be lowered to 70 °C, the reaction was complete in less than 30
min, and only the desired arabinofuranoside product was produced.
While our initial thoughts were that the chirality of the additive
was essential, that was shown not to be the case.[21] The reasons underlying this effect remain unclear, but
the presence of a free OH group at C-5 in 19 (either
present initially or liberated under the basic conditions of the reaction)
is essential for good regiocontrol. Presumably, a ternary complex
(e.g., 21) between the lithium ion, the (−)-sparteine,
and the substrate forms, which then directs the nucleophile to C-3.
However, attempts to determine the structure of this intermediate
have been unsuccessful.Although we did not elucidate reasons
for the high regioselectivity
in the epoxide ring opening in glycosides of the type 19, we did succeed in understanding the origins of the selectivity
in the glycosylation reactions with 2,3-anhydro-furanoside sulfoxides.[23] Using experimental techniques pioneered by Crich,[18] coupled with ab initio calculations, we demonstrated
that the origin of the high stereoselectivity was due to the formation
of an intermediate α-glycosyl triflate that underwent an SN2-like nucleophilic displacement by the nucleophile. Thus,
these reactions proceed in a way analogous to the Crich β-mannoside
method,[19] with the epoxide serving as the
conformational restraint.The 2,3-anhydrosugar methodology could
be applied to the preparation
of complex arabinans, including the Ara6 motif (10, Figure ), and it was also
extended to hexofuranosides through the preparation of α-galactofuranosides
by graduate student Yu Bai.[24,25] Nevertheless, the two
step approach and the rather complex conditions required for the epoxide
ring opening prompted us to explore other conformationally restricting
groups that could achieve the same effect. Our initial focus was on
groups that spanned O-2 and O-3 of the arabinofuranose ring, in particular 22 and 23 (Figure ). Unfortunately, we were never able to produce these
compounds in yields sufficient for further studies. While engaged
in these investigations, we were “scooped” by Boons[26] and soon after Ito.[27] Both groups reported that conformational restriction of the arabinofuranose
ring through O-3/O-5, using silyl-based protecting groups, provided
reagents (e.g., 24 and 25) that were highly
β-selective. The rationale for the selectivity builds from the
“inside-attack” model proposed by Woerpel and co-workers
to predict the stereoselectivity of nucleophilic attack onto five-membered
ring oxacarbenium ions.[28] The silyl protecting
group effectively locks the five-membered ring into an envelope conformation
that is predisposed to attack leading to the β-glycoside.
Figure 7
Conformationally
restricted arabinofuranose donors (22–25, 27) and an O-5 substituted
β-arabinofuranoside motif present in mycobacterial LAM (26).
Conformationally
restricted arabinofuranosedonors (22–25, 27) and an O-5 substituted
β-arabinofuranoside motif present in mycobacterial LAM (26).While regents such as 24 and 25 are very
useful, and generally superior to 2,3-anhydrosugardonors, they have
limitations with regard to the preparation of β-arabinofuranosides
that are substituted on O-5. Such motifs (e.g., 26) are
present in mycobacterial LAM.[2] The use
of O-3/O-5-protected reagents to prepare compounds of this type requires
a number of transformations after introduction of the β-Araf residue. To address this limitation, a postdoctoral fellow,
Aki Imamura, explored the use of another class of donors possessing
conformational restriction across O-2 and O-3: 2,3-O-xylylene-protected thioglycosides (e.g., 27). Whereas
our attempts to prepare 22 and 23 had failed,
compounds of the general class 27 could be prepared straightforwardly.
When explored in glycosylation reactions,[29] we were pleased to discover that these compounds, like 24 and 25, are indeed generally β-selective, thus
allowing straightforward access to compounds such as 26. Following glycosylation, the O-5 protecting group can be cleaved,
allowing further modification at that position.The studies
described above, as well as work carried out by others,
have led to an arsenal of methods for the synthesis of essentially
any mycobacterial arabinan fragment. Such syntheses can now be done
with confidence and an increasingly diverse range of compounds have
now been synthesized.[30−37] Notable among these are large fragments of these molecules including
species with more than 20 Araf residues.[38−40] Access to these compounds is now facilitating downstream biological/immunological
investigations, including mapping of the epitopes of anti-LAM monoclonal
antibodies,[41,42] the development of novel anti-TB
vaccines,[37] and characterization of the
specificity of the immune response that arises from LAM.
Synthesis of
Mannopyranosides
A desire to carry-out structure–function
studies of the
biological role of LAM has led to interest in synthesizing fragments
containing both Araf and mannopyranose (Manp) residues.[31,37,43−46] The Manp residues in LAM are α-(1→2)-,
α-(1→6)-, and, in one strain, α-(1→3)-linked.[3] α-Manp residues in these
linkages are found in a broad range glycoconjugates and are generally
straightforward to prepare. In most cases, established approaches
have led to the successful preparation of these molecules, although
streamlined methods specific to these fragments have been reported.[47]
Synthesis of Galactofuranosides
Several years after initiating the work on arabinofuranosides,
we turned our attention to the other major furanose component in the
mycobacterial cell wall: the galactan domain of the AG. Our interest
was motivated by the identification of a galactofuranosyltransferase
enzyme,[48] which, at the time, appeared
to be the primary glycosyltransferase involved in galactan biosynthesis.
Compared with the arabinan, the galactan is relatively simple. It
is a linear chain of alternating β-(1→5) and β-(1→6)-linked
Galf residues, attached to a disaccharide containing
rhamnose and N-acetylglucosamine.[2] Moreover, the linkages between the Galf residues are 1,2-trans, and hence we envisioned
that the assembly of galactan fragments would be straightforward through
the use of donors with acyl protecting groups on O-2. We were aware
of the pioneering work on galactofuranoside synthesis done by de Lederkremer,
particularly the development and application of suitable donor and
acceptor species, and our work was informed by those previous investigations.[49−51]Although access to Galf derivatives via a
kinetically
controlled Fischer glycosylation is possible,[52] significant amounts of pyranosides are often formed, which greatly
complicates purification. For this reason, we generally access Galf derivatives through the cyclization of the readily prepared
galactose diethyl dithioacetal (28, Scheme ). This method, which dates
to the 1930s,[53] is robust, and through
the use of iodine as a promoter,[54] we have
used it to prepare both methyl and octyl galactofuranosides, 29 and 30, respectively.[55] The former can be acylated and then converted into the corresponding
thioglycoside (31) and in turn the trichloroacetimidate 32. In continuation of this work, graduate student Gladys
Completo then showed that 31 and 32 are
useful donors for the preparation of β-Galf-containing oligosaccharides (e.g., 33 and 34, Figure ), by both
traditional and one-pot approaches.[55]
Scheme 2
Access to the Galactofuranose Ring System from Dithioacetal 28 and Donors (31 and 32) Used in
the Synthesis of β-Galactofuranosides
Figure 8
Representative structures of synthetic β-galactofuranoside
fragments of mycobacterial AG.
Representative structures of synthetic β-galactofuranoside
fragments of mycobacterial AG.Using the general approaches outlined above, both we[55] and others[56,57] have synthesized
a range of galactofuranosides. Such compounds have found significant
application in studying mycobacterial galactan biosynthesis, in particular
the two transferase enzymes involved in that process, GlfT1 and GlfT2.[58] Such studies have included kinetics studies
of the enzyme,[59] the evaluation of active
site probes,[60−66] and X-ray crystallographic investigations.[67]
Other Mycobacterial Cell Wall Glycans
After developing approaches
for the synthesis of the furanoside-containing
glycans of the mycobacterial cell wall, we looked to another fascinating
group of structures present in this complex assembly: the “extractable”
glycolipids.[68] These species are found
intercalated into the mycolic acid layer of the organism (Figure ) and often serve
as modulators of the host immune system.[69] The extractable lipids can be grouped into four general classes:
phenolic glycolipids (PGLs, e.g, 34, Figure ),[69] glycopeptidolipids (GPLs, e.g., 35),[70] trehalose mycolates (e.g., 36), and lipooligosaccharides
(LOSs, e.g., 37).[5] These molecules
are produced in a species specific manner. That is, not all mycobacterial
strains synthesize all of the structures, and moreover, the molecules
that are produced generally differ across species. Although the immunomodulatory
properties of the extractable lipids are well established, detailed
structure–function studies were not available when we began
to consider synthesizing these compounds. We therefore set as a goal
the synthesis of all known representatives of these glycolipids, both
as the free glycan and as their lipidated (natural) forms. It was
anticipated that access to such a library would greatly facilitate
the development of a molecular-level appreciation of how these molecules
interact with the immune system of the host.
Figure 9
Representative structures
of phenolic glycolipids (34), glycopeptidolipids (35), trehalose mycolates (36), and lipooligosaccharides
(37).
Representative structures
of phenolic glycolipids (34), glycopeptidolipids (35), trehalose mycolates (36), and lipooligosaccharides
(37).On the surface, these
molecules seem to be more straightforwardly
accessible than the LAM and AG fragments described above. Indeed,
while there is considerable prior art that could be used to develop
synthetic routes to the extractable glycolipids, there are nevertheless
challenges. One is the preparation of the unusual monosaccharides
present in many of the targets (e.g., 37). Another is
the development of strategies that allow the introduction of fatty
acyl acids, which effectively precludes the use of most ester protecting
groups.Mindful of these challenges, we first targeted what
we considered
to be the most tractable of the extractable glycolipids: PGLs. Although
there is now a total synthesis of a complete PGL,[71] that paper had not appeared when we began our investigations.
At the outset, to probe the effect of the glycan on cytokine function
in the absence of the lipid domain, we targeted a family of all of
the reported PGL structures, prepared as their p-methoxyphenyl
glycosides (e.g., 38, 39, Figure ).[72−74] This work,
done by a single graduate student, Hassan Elsaidi, was a significant
undertaking. It was envisioned that the p-methoxyphenyl
aglycone would serve as a suitable surrogate for the phenyl group
of the native PGLs. Moreover, the presence of this group could facilitate
the synthesis of more complex analogs, through its selective cleavage[75] and then coupling of the resulting oligosaccharide
to other aglycones. In addition, strategies for the introduction of
the methyl groups that characterize these species were investigated.
In most cases it turned out to be more efficient to carry out methylation
on the monosaccharide building blocks rather than on the more complex
oligosaccharide products.
Figure 10
Synthetic PGL analogs used to probe cytokine
modulation.
Synthetic PGL analogs used to probe cytokine
modulation.After synthesizing the
panel of more than 25 compounds, Hassan
then evaluated their ability modulate the activity of proinflammatory
cytokines (e.g., TNF-α) and nitric oxide. Although none of the
compounds were inducers of these cytokines, many inhibited their production
and these effects were structure dependent. Hassan went on to demonstrate
that replacement of the aryl methoxy group with a longer, and yet
still simple, lipid (40) enhanced this effect. Moreover,
the potency of this compound approached that for phenolic glycolipid
1 (PGL-1) from Mycobacterium leprae, the only PGL
available in usable quantities for purposes of comparison. Through
these studies, we could conclude that the carbohydrate domain is essential
for the ability of these molecules to inhibit the production of proinflammatory
cytokines and that addition of a lipid domain enhances the effect,
although the complex lipid present in the natural product appears
not to be required for activity.
Conclusions and Future
Directions
Through our studies of the last 20 years, we have
systematically
developed approaches for the chemical synthesis of mycobacterial cell
wall glycans and then applied them to the preparation of a range of
target molecules. The compounds we and others have made are increasingly
being used in studies to probe the biosynthesis and biological function
of the fascinating glycans produced by mycobacteria. Given the importance
of tuberculosis as a global health threat, such studies will impact
the development of novel drugs for treating mycobacterial disease,
novel vaccines for preventing them, and new diagnostics. Current efforts
in the group are focused on broadening our collection of extractable
lipids structures, with a particular emphasis on the glycopeptidolipids
and the lipooligosaccharides.[76]
Authors: L Kremer; L G Dover; C Morehouse; P Hitchin; M Everett; H R Morris; A Dell; P J Brennan; M R McNeil; C Flaherty; K Duncan; G S Besra Journal: J Biol Chem Date: 2001-04-13 Impact factor: 5.157
Authors: Rajendrakumar Reddy Gadikota; Christopher S Callam; Timothy Wagner; Brian Del Fraino; Todd L Lowary Journal: J Am Chem Soc Date: 2003-04-09 Impact factor: 15.419
Authors: Christopher S Callam; Rajendrakumar Reddy Gadikota; Douglas M Krein; Todd L Lowary Journal: J Am Chem Soc Date: 2003-10-29 Impact factor: 15.419
Authors: Stefan van der Vorm; Thomas Hansen; Erwin R van Rijssel; Rolf Dekkers; Jerre M Madern; Herman S Overkleeft; Dmitri V Filippov; Gijsbert A van der Marel; Jeroen D C Codée Journal: Chemistry Date: 2019-04-17 Impact factor: 5.236
Authors: Thomas Hansen; Tim P Ofman; Joey G C Vlaming; Ivan A Gagarinov; Jessey van Beek; Tessa A Goté; Jacoba M Tichem; Gijs Ruijgrok; Herman S Overkleeft; Dmitri V Filippov; Gijsbert A van der Marel; Jeroen D C Codée Journal: Angew Chem Int Ed Engl Date: 2020-11-03 Impact factor: 16.823